New combo therapy aims for drug-free remission in CML patients who relapsed before

NCT ID NCT03610971

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 20 times

Summary

This study tests whether adding ruxolitinib to a standard tyrosine kinase inhibitor (TKI) can help people with chronic myeloid leukemia (CML) achieve a lasting remission after stopping all treatment. Participants are adults with CML who previously tried to stop their TKI but relapsed. The goal is to see if the combination allows them to stay in remission without needing lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering

    New York, New York, 10021, United States

  • Duke University Hospital

    Durham, North Carolina, 27710, United States

  • Emory -Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Memorial Sloan Kettering - Bergen

    Montvale, New Jersey, 07645, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.